| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,326 | 2,358 | 22.04. | |
| 0,000 | 0,000 | 22.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 20,000 | 400 | |||
| 12,800 | 375 | |||
| 9,990 | 1.400 | |||
| 9,900 | 100 | |||
| 7,250 | 5.000 | |||
| 5,500 | 2.000 | |||
| 5,100 | 200 | |||
| 4,950 | 3.000 | |||
| 3,500 | 1.000 | |||
| 2,341 | 3.101 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ayj.htm [/URL] | ||||
| 3.101 | 2,309 | |||
| 1.000 | 2,280 | |||
| 100 | 1,990 | |||
| 70 | 1,860 | |||
| 1.000 | 0,037 | |||
| 1.068 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 6.339 | 2,615 | 16.576 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:29:19 | 2,383 | 3 |
| 17:29:19 | 2,383 | 2 |
| 17:27:38 | 2,381 | 17 |
| 17:26:50 | 2,380 | 1 |
| 17:21:24 | 2,381 | 37 |
| 17:21:24 | 2,381 | 41 |
| 17:21:24 | 2,381 | 7 |
| 17:17:40 | 2,370 | 1.200 |
| 17:16:08 | 2,370 | 393 |
| 17:16:08 | 2,372 | 20 |
| 17:16:08 | 2,372 | 242 |
| 17:16:08 | 2,378 | 258 |
| 17:16:08 | 2,378 | 682 |
| 17:07:06 | 2,388 | 4 |
| 16:50:53 | 2,408 | 8 |
| 16:45:05 | 2,392 | 624 |
| 16:44:59 | 2,396 | 88 |
| 16:44:59 | 2,396 | 400 |
| 16:37:24 | 2,421 | 33 |
| 16:32:10 | 2,416 | 16 |
| Tagesumsatz Xetra | -0,193 -7,46 % | 165.610 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | EILMELDUNG bei Valneva: Der Kurs nähert sich einer gefährlichen Marke - So reagieren erfahrene Anleger jetzt | Hebelschein-Spekulant | |||
| Mi | Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty | 173 | Investing.com | ||
| Mi | Goldman Sachs stuft Valneva wegen Unsicherheit bei Borreliose-Impfstoff auf "Verkaufen" herab | 274 | Investing.com Deutsch | ||
| 16.04. | Guggenheim senkt Kursziel für Valneva-Aktie wegen Lyme-Impfstoff auf 11 US-Dollar | 298 | Investing.com Deutsch | ||
| VALNEVA Aktie jetzt für 0€ handeln | |||||
| 03.04. | Declaration of shares and voting rights of Valneva SE - March 2026 | 134 | GlobeNewswire (USA) |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | AFX News | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| Mi | GenScript Biotech Corporation: GenScript Leaders Named Entrepreneur Of The Year 2026 New Jersey Finalists | PR Newswire | PISCATAWAY, N.J., April 22, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as finalists for the... ► Artikel lesen | |
| Mi | Humacyte, Inc: Humacyte Appoints Jim Mercadante as Chief Commercial Officer | GlobeNewswire (Europe) | - Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion - - Seasoned medtech commercial leader brings extensive field-specific success... ► Artikel lesen | |
| Mi | Degroof Petercam Initiates Medincell's Coverage with a "Buy" Recommendation | Business Wire | Degroof Petercam, a leading European investment bank with strong healthcare expertise, has initiated coverage of Medincell In a report entitled "Royalty flywheel approaching profitability", the... ► Artikel lesen | |
| Mi | RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | PR Newswire | New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of... ► Artikel lesen |